Development of a Novel Peptide-Based PET Tracer [⁶⁸Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma

Abstract

B-cell maturation antigen (BCMA) has emerged as a promising tumor marker for the diagnosis and treatment of multiple myeloma. The noninvasive and rapid detection of BCMA expression in vivo provides significant value in screening and evaluating multiple myeloma patients receiving BCMA-targeted therapy. We identified the BCMA-targeting peptide BP1 from a one-bead-one-compound (OBOC) peptide library using a highthroughput microarray strategy. The BCMA-targeting specificity and affinity of BP1 were assessed by surface plasmon resonance imaging (SPRi), flow cytometry, and confocal imaging. BCMApositive (H929) and BCMA-negative (K562) subcutaneous tumor models were established and labeled with 68 Ga for BP1, followed by PET imaging and biodistribution studies. PET imaging demonstrated that 68 Ga-labeled BP1 has significant specific uptake in multiple myeloma, enabling rapid identification of BCMA expression and precise delineation of the disease. Thus, BP1 represents an ideal candidate for multiple myeloma imaging.